Lung Cancer Treatment Market - By Type (Carcinoid, Non-small & Small Cell), By Therapy [(Radiation, Immunotherapy (Durvalumab), Targeted (Bevacizumab), Chemotherapy], By End-user (Hospitals, Specialty Clinics, Homecare), Global Forecast, 2023-2032

Description

List of Tables

Global Lung Cancer Treatment Market size will grow substantially during 2023-2032. Rising air pollution levels due to accelerating urbanization and industrial growth worldwide have resulted in increased incidences of lung cancer, bolstering the need for its treatment. As per the WHO, ambient air pollution is projected to lead to 16% of lung cancer deaths, while air pollution may be responsible for around 29% of the deaths caused by lung cancer globally. The increasing disease burden has bolstered awareness about its early diagnosis and treatment to prevent further complications, contributing to market growth.

The overall lung cancer treatment market is segmented based on type, therapy, end-user, and region.

Based on type, the market share from the carcinoid segment will depict significant growth through 2032. Growing prevalence of lung cancer and high mortality rate associated with it has increased the need for its treatment. According to the American Cancer Society, the U.S. reports around 2,000 to 4,500 lung carcinoid tumors every year. Moreover, improved diagnostic techniques and the rising awareness of carcinoid tumors have propelled the number of patients undergoing treatment of this condition, thus, adding to market revenue.

In terms of therapy, the lung cancer treatment market value from the chemotherapy segment will accrue significant gains through 2032. Advances in genomics and molecular profiling have enabled personalized medicine in chemotherapy. By analyzing a patient's tumor at a molecular level, doctors can identify specific genetic mutations or biomarkers that drive the cancer's growth. This information helps tailor the chemotherapy regimen to target those specific abnormalities, increasing treatment effectiveness.

Based on end-user, the lung cancer treatment market from the specialty clinics segment will observe appreciable growth over 2023-2032. High availability of cutting-edge diagnostic equipment has made specialty clinics a preferred healthcare provider. Additionally, these facilities are well-positioned to provide personalized care tailored to specific patient needs. They offer comprehensive evaluations, molecular profiling, and access to clinical trials, ensuring that patients receive the most appropriate and effective treatment options.

Regionally, Europe lung cancer treatment industry will grow at a decent CAGR from 2023 to 2032. High incidence rate of lung cancer has increased the need for its treatment in the region. Moreover, a strong presence of industry contenders such as Boehringer Ingelheim International GmbH, Merck KGaA, and others constantly focusing on developing advanced treatment options for lung cancer is positively impacting the regional market growth. Additionally, the rapid expansion of the existing healthcare infrastructure in the region will stimulate industry revenue streams through 2032.

Product Code: 5708

Chapter 1 Methodology & Scope

1.1 Industry coverage
1.2 Market definitions
1.3 Base estimates and calculations
1.4 Forecast calculations
1.5 Data sources
1.6 Data validation
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Lung Cancer Treatment industry 360 degree synopsis, 2018 - 2032 (USD Million)
- 2.1.1 Business trends
- 2.1.2 Type trends
- 2.1.3 By Therapy trends
- 2.1.4 End-user trends
- 2.1.5 Regional trends

Chapter 3 Lung Cancer Treatment Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of lung cancer across the globe
  - 3.2.1.2 The growing trend of smoking tobacco
  - 3.2.1.3 Rising levels of air pollution due to rapid industrialization
  - 3.2.1.4 Increasing emphasis on early diagnosis of cancers
  - 3.2.1.5 Rising technological advancements in lung cancer treatment
  - 3.2.1.6 Availability of reimbursement for lung cancer treatment
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 The high cost of lung cancer treatments
  - 3.2.2.2 Side effects of drugs and therapies
3.3 Growth potential analysis
- 3.3.1 By type
- 3.3.2 By therapy
- 3.3.3 By end-user
3.4 COVID-19 impact analysis
3.5 Clinical trial analysis
3.6 Regulatory landscape
- 3.6.1 U.S.
- 3.6.2 Europe
3.7 Technology landscape
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Competitive dashboard, 2022
4.3 Company matrix analysis, 2022
4.4 Company market share analysis, 2022
4.5 Competitive positioning matrix, 2022
4.6 Strategic outlook matrix, 2022

Chapter 5 Lung Cancer Treatment Market Estimates and Forecast, By Type (USD Million)

5.1 Key trends, by type
5.2 Non-small cell lung cancer
5.3 Small cell lung cancer
5.4 Carcinoid

Chapter 6 Lung Cancer Treatment Market Estimates and Forecast, By Therapy (USD Million)

6.1 Key trends, by therapy
6.2 Radiation therapy
6.3 Immunotherapy
6.4 Targeted therapy
6.5 Chemotherapy
6.6 Other therapies

Chapter 7 Lung Cancer Treatment Market Estimates and Forecast, By End-user (USD Million)

7.1 Key trends, by end-user
7.2 Hospitals
7.3 Specialty clinics
7.4 Homecare
7.5 Other end-users

Chapter 8 Lung Cancer Treatment Market Size and Forecast, By Region (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 MEA
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 Rest of Middle East & Africa

Chapter 9 Company Profiles

9.1 Merck KGaA
9.2 ONO PHARMACEUTICAL CO., LTD.
9.3 Boehringer Ingelheim International GmbH
9.4 GlaxoSmithKline plc.
9.5 Pfizer Inc.
9.6 Johnson & Johnson Services, Inc.
9.7 AstraZeneca
9.8 Takeda Pharmaceutical Company Limited
9.9 Church & Dwight Co., Inc.
9.10 Sun Pharmaceutical Industries Ltd.Takara Bio Inc.